Biocept, Inc. (BIOC)
| Market Cap | 80.78M |
| Revenue (ttm) | 10.73M |
| Net Income (ttm) | -25.45M |
| Shares Out | 11.32M |
| EPS (ttm) | -2.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $6.03 |
| Previous Close | $6.24 |
| Change ($) | -0.21 |
| Change (%) | -3.37% |
| Day's Open | 6.26 |
| Day's Range | 5.64 - 6.39 |
| Day's Volume | 329,838 |
| 52-Week Range | 2.11 - 13.00 |
Biocept Inc (NASDAQ: BIOC) will collaborate with Protean BioDiagnostics Inc to research Biocept's Target Selector molecular assay's ability to determine EGFR status in non-small cell lung canc...
Biocept Inc (NASDAQ:BIOC) announced plans Tuesday to collaborate with Protean BioDiagnostics Inc to research the ability of its own Target Selector molecular assays to determine the status of ...
SAN DIEGO--(BUSINESS WIRE)--Biocept and Protean BioDiagnostics Collaborate to Demonstrate Advantages of Biocept's Target Selector Assay for Non-Small Cell Lung Cancer Patients.
Biocept Inc (NASDAQ:BIOC) announced Tuesday that its Target Selector molecular assay kit detected mutations in up to 50% of tissue biopsy specimens from non-small cell lung cancer patients tha...
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will present data showing that its Target Selector™ molecula...
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, provides an upd...
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically act...
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular testing to provide physicians with clinically actionable information to improve patient out...
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with cl...
SAN DIEGO, Dec. 31, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with c...
SAN DIEGO, Dec. 30, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with c...
SAN DIEGO, Nov. 20, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with c...
Biocept, Inc. (BIOC) CEO Michael Nall on Q3 2020 Results - Earnings Call Transcript
SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with c...
SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, an...
SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with cl...
SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests, products and services designed to provide physicians with cli...
SAN DIEGO, Oct. 29, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, an...
SAN DIEGO, Sept. 4, 2020 /PRNewswire/ -- Biocept, Inc.
SAN DIEGO, Aug. 31, 2020 /PRNewswire/ -- Biocept, Inc.
SAN DIEGO, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable info...
SAN DIEGO, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable in...
SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable i...
Biocept, Inc. (BIOC) CEO Michael Nall on Q2 2020 Results - Earnings Call Transcript
SAN DIEGO, Aug. 12, 2020 /PRNewswire/ -- Biocept, Inc.
Biocept (BIOC) is expected to have suffered in Q2 from reduced oncology practices and postponement of patient appointments.
SAN DIEGO, Aug. 6, 2020 /PRNewswire/ -- Biocept, Inc.
SAN DIEGO, Aug. 3, 2020 /PRNewswire/ -- Biocept, Inc.
These seven penny stocks have the right catalysts, business models, and tailwinds. Read about why the risk is worth it.
SAN DIEGO, July 16, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable informa...
SAN DIEGO, June 30, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable informa...
SAN DIEGO, June 24, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable informa...
SAN DIEGO, June 22, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable informa...
SAN DIEGO, June 5, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable informat...
SAN DIEGO, May 20, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable informat...
SAN DIEGO, May 14, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable informat...
Biocept, Inc. (BIOC) CEO Michael Nall on Q1 2020 Results - Earnings Call Transcript
As the COVID-19 pandemic continues to ravage the globe, having claimed over 115,000 lives, health care companies have are pursuing diagnostics tests, potential vaccines and therapies.
Biocept, Inc. (BIOC) CEO Michael Nall on Q4 2019 Results - Earnings Call Transcript
Shares of Biocept Inc. BIOC, -42.27% plummeted 42% on very heavy volume in morning trading Monday, after the provider of liquid cancer tests announced the pricing of stock offering at a deep d...
Speculative Spotlight: Biocept Is Undervalued Despite Commercial Progress
Biocept, Inc. (BIOC) CEO Michael Nall on Q3 2019 Results - Earnings Call Transcript
Biocept, Inc. (BIOC) CEO Michael Nall on Q2 2019 Results - Earnings Call Transcript
Shares of Biocept Inc. BIOC, +84.16% soared 86% on very heavy volume Monday, after the provider of liquid biopsy tests announced the commercial launch of Target Selector NGS Lung Panel, the li...
Shares of Biocept Inc (NASDAQ: BIOC), a molecular diagnostics company specializing in biomarker analysis of circulating tumor-associated DNA, are making a strong upward move Monday.
Biocept, Inc. (BIOC) CEO Michael Nall on Q1 2019 Results - Earnings Call Transcript
Biocept, Inc. (BIOC) CEO Michael Nall on Q4 2018 Results - Earnings Call Transcript
About BIOC
Biocept, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, smal... [Read more...]
| Industry Diagnostics & Research | IPO Date Feb 5, 2014 |
| CEO Michael Nall | Employees 88 |
| Stock Exchange NASDAQ | Ticker Symbol BIOC |
Financial Performance
In 2019, Biocept's revenue was $5.53 million, an increase of 70.09% compared to the previous year's $3.25 million. Losses were -$25.14 million, 2.31% more than in 2018.
Analyst Forecasts
According to one analyst, the rating for Biocept stock is "Buy" and the 12-month stock price forecast is 20.00.